drug · small molecule
zipalertinib
pre_registrationupdated 5mo agoby Taiho Pharmaceutical Co Ltd🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3, with 1 investigational indication.
indications
indications
NSCLC
targets
Epidermal growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying zipalertinib
- phase2Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
- phase3A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- phase2Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
News(6)
- Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefitAnalysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…biospace · 19d ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 23d ago
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 1mo ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 1mo ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 1mo ago
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that